Xiaochuang Medical closes angel+ round led by Oriza Holdings for duodenal PFA

What's the deal? Xiaochuang Medical, a Chinese medtech startup developing devices for digestive and metabolic diseases, has closed an angel+ funding round. The round was led by Oriza HoldingsDealroom has a profile for this one. Try Dealroom →, with co-investment from Suzhou High-tech District Sci-Tech Angel Fund and Shanghai Hongye. The company plans to use the capital to advance clinical trials for its core products and accelerate commercialisation.

Why now? Xiaochuang focuses on duodenal pulsed field ablation (PFA), a frontier technique that uses electrical pulses to ablate tissue in the duodenum. The approach targets metabolic conditions like type 2 diabetes and obesity — areas of surging global demand — without the permanence or risks of surgical intervention. As PFA gains traction in cardiology, applying it to gastrointestinal conditions represents a new and potentially large market.

What could go wrong? Duodenal PFA remains an early-stage technology with limited clinical data. Regulatory approval timelines in China and beyond are uncertain, and the startup will need to demonstrate clear safety and efficacy advantages over existing treatments. Competition from established medtech players developing similar metabolic-disease devices could also intensify.

The signal: The deal reflects growing investor appetite for minimally invasive solutions to metabolic diseases — a category long dominated by pharmaceuticals and bariatric surgery. It also underscores continued Chinese state-backed fund participation in early-stage medtech, with both a municipal angel fund and a major state-owned holding company backing the round.